Markets:

Overview

News

Currencies

International

Treasuries

Denium Therapeutics, Inc - Common Shares (NQ:MNMD)

14.87 +0.99 (+7.13%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Denium Therapeutics, Inc - Common Shares

< Previous 1 2 3 4 5 6 7 8 9

...

28 29 Next >

Psychedelics Break Out Of The Fringe Under RFK Jr’s 2025 Reset — But Did MNMD Or CMPS Own The Year? ↗

December 24, 2025

Regulatory thaw, political backing, and late-stage data are propelling psychedelic drugmakers into the biotech spotlight — with Compass Pathways and Mind Medicine leading the charge.

Via Stocktwits

Topics ETFs

MarketBeat’s Top 5 Rated Small-Cap Stocks ↗

December 22, 2025

Via MarketBeat

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Reports Q3 2025 Earnings Miss Amid Accelerated Clinical Pipeline Spending ↗

November 06, 2025

MindMed reports a wider-than-expected Q3 2025 loss as it accelerates its late-stage clinical trials for MM120, targeting anxiety and depression.

Via Chartmill

Topics Earnings

MindMed (MNMD) Q3 2025 Earnings Call Transcript ↗

November 06, 2025

MindMed (MNMD) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Earnings Scheduled For July 31, 2025 ↗

July 31, 2025

Via Benzinga

Earnings Scheduled For May 8, 2025 ↗

May 08, 2025

Via Benzinga

Why Mind Medicine Stock Is Skyrocketing Today ↗

February 14, 2025

Via The Motley Fool

Why Mind Medicine Stock Is Soaring Today ↗

January 07, 2025

Via The Motley Fool

Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression ↗

October 13, 2025

Needham starts MindMed at Buy with a $28 target, citing strong Phase 3 prospects for MM120 in anxiety and depression and solid cash position.

Via Benzinga

The Insider Report: Panic Never Pays ↗

October 11, 2025

Via Benzinga

If You'd Invested $1,000 in Mind Medicine (MNMD) Stock 5 Years Ago, Here's How Much You'd Have Today ↗

August 12, 2025

Mind Medicine stock hasn't beaten the market over the last five years, but what comes next?

Via The Motley Fool

MindMed (MNMD) Q2 2025 Earnings Call Transcript ↗

August 11, 2025

Via The Motley Fool

Topics Earnings Initial Public Offering

MindMed Reports Strong Q2 2025 Results ↗

August 11, 2025

Via The Motley Fool

1 Reason to Buy MindMed (MNMD) ↗

August 07, 2025

The U.S. public and the nation's politicians seem to be coming around to the idea of reforming psychedelic drug laws. Looser restrictions on research would help this company.

Via The Motley Fool

Topics Cannabis Law Enforcement

MindMed (MNMD) Q2 Net Loss Jumps 625% ↗

August 01, 2025

Via The Motley Fool

Topics Intellectual Property

Why Mind Medicine Gave Investors a Powerful Buzz in May ↗

June 04, 2025

Via The Motley Fool

Topics Law Enforcement

Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors ↗

May 24, 2025

Psychedelics litigator Matthew Zorn joins HHS under RFK Jr. to lead policy. What it means for CMPS, MNMD, CYBN, PSIL & more.

Via Benzinga

Topics Government

Why Mind Medicine Stock Vaulted More Than 8% Higher Today ↗

May 20, 2025

Via The Motley Fool

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

May 20, 2025

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday.

Via Chartmill

Agilysys, Amer Sports, X Financial And Other Big Stocks Moving Higher On Tuesday ↗

May 20, 2025

Via Benzinga

The Future of Healthcare: 10 Predictions For The Next Decade

March 27, 2025

The healthcare industry stands on the brink of a transformative decade, driven by rapid advancements in technology, shifting demographics, and evolving patient expectations. Over the next ten years, we...

Via MarketMinute

Topics Artificial Intelligence

Gap To Rally Over 69%? Here Are 10 Top Analyst Forecasts For Friday ↗

March 07, 2025

Via Benzinga

Mind Medicine's Net Losses Swell In Q4, But Retail Finds At Least 3 Reasons To Stay Bullish ↗

March 06, 2025

The psychedelics treatment developer reported a net loss of $34.7 million for the quarter ended Dec. 31, 2024, widening from a $23.8 million loss a year earlier.

Via Stocktwits

Warren Buffett's State of the Market ↗

March 03, 2025

Berkshire's cash hoard is approaching "Dr. Evil" levels.

Via The Motley Fool

Mind Medicine Getting An 'RFK Bump'? Retail Gets More Bullish As Stock Heads For Best Day In Over 10 Months ↗

February 14, 2025

Kennedy has previously advocated for decriminalizing psychedelics for therapeutic use, citing his son’s positive experience with the hallucinogenic brew ayahuasca.

Via Stocktwits

RFK Jr. Confirmation Looms. How Kennedy Could 'Go Wild' On Health Care. ↗

February 12, 2025

The Senate will vote Thursday on whether to put RFK Jr. in charge of health. It's unclear how he will impact biotech stocks.

Via Investor's Business Daily

Earnings Scheduled For March 6, 2025 ↗

March 06, 2025

Via Benzinga

Mind Medicine Stock Rises As Evercore Projects 200% Upside On LSD Formulation: Retail Turns Bullish ↗

January 28, 2025

The brokerage also pointed to potential large-scale expansion opportunities and emphasized the growing acceptance of psychedelics in future treatment paradigms.

Via Stocktwits

This Westlake Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

January 28, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

28 29 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.